http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 20 Feb 2026 16:10:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++KAZIA+THERAPEUTICS+LTD+++++++++++++++++Filed+by%3A+Chernett+Jorey/26036110.html si-local-file:///var/storage/secattach/20260220/26036110.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++KAZIA+THERAPEUTICS+LTD+++++++++++++++++Filed+by%3A+Chernett+Jorey/26036110.html Fri, 20 Feb 2026 16:10:00 -0500 KZIA O.00673961 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++KAZIA+THERAPEUTICS+LTD+++++++++++++++++Filed+by%3A+Chernett+Jorey/26036110.html si-local-file:///var/storage/secattach/20260220/26036110.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++KAZIA+THERAPEUTICS+LTD+++++++++++++++++Filed+by%3A+Chernett+Jorey/26036110.html Fri, 20 Feb 2026 16:10:00 -0500 KZIA O.00673961 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++KAZIA+THERAPEUTICS+LTD+++++++++++++++++Filed+by%3A+Ikarian+Capital%2C+LLC/26015512.html si-local-file:///var/storage/secattach/20260217/26015512.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++KAZIA+THERAPEUTICS+LTD+++++++++++++++++Filed+by%3A+Ikarian+Capital%2C+LLC/26015512.html Tue, 17 Feb 2026 17:48:00 -0500 KZIA O.00673961 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++KAZIA+THERAPEUTICS+LTD+++++++++++++++++Filed+by%3A+Ikarian+Capital%2C+LLC/26015512.html si-local-file:///var/storage/secattach/20260217/26015512.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++KAZIA+THERAPEUTICS+LTD+++++++++++++++++Filed+by%3A+Ikarian+Capital%2C+LLC/26015512.html Tue, 17 Feb 2026 17:48:00 -0500 KZIA O.00673961 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++KAZIA+THERAPEUTICS+LTD+++++++++++++++++Filed+by%3A+Dauntless+Investment+Group%2C+LLC/25992117.html si-local-file:///var/storage/secattach/20260212/25992117.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++KAZIA+THERAPEUTICS+LTD+++++++++++++++++Filed+by%3A+Dauntless+Investment+Group%2C+LLC/25992117.html Thu, 12 Feb 2026 16:16:00 -0500 KZIA O.00673961 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++KAZIA+THERAPEUTICS+LTD+++++++++++++++++Filed+by%3A+Dauntless+Investment+Group%2C+LLC/25992117.html si-local-file:///var/storage/secattach/20260212/25992117.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++KAZIA+THERAPEUTICS+LTD+++++++++++++++++Filed+by%3A+Dauntless+Investment+Group%2C+LLC/25992117.html Thu, 12 Feb 2026 16:16:00 -0500 KZIA O.00673961 http://www.streetinsider.com/Corporate+News/Kazia+Therapeutics+reports+preclinical+data+for+cancer+drug+NDL2/25919928.html <p>Kazia Therapeutics (NASDAQ: KZIA) announced preclinical and translational data for NDL2, a protein degrader designed to target nuclear PD-L1, according to a company statement. The Sydney-based oncology company said the compound addresses what it describes as a previously unrecognized driver of immunotherapy resistance and metastatic progression.</p><p>The data were generated by Professor Sudha Rao and her team at QIMR Berghofer. In murine triple-negative breast cancer models, NDL2 reduced primary tumor volume by 49% as monotherapy and 73% when combined with anti-PD-1 therapy, with a 50% reduction in lung metastases in the combination setting, according to the company.</p><p>Unlike existing PD-1/PD-L1 antibodies that http://www.streetinsider.com/Corporate+News/Kazia+Therapeutics+reports+preclinical+data+for+cancer+drug+NDL2/25919928.html Fri, 30 Jan 2026 08:00:31 -0500 KZIA http://www.streetinsider.com/FDA/Kazia+Therapeutics+reports+preclinical+data+for+cancer+drug+NDL2/25919928.html <p>Kazia Therapeutics (NASDAQ: KZIA) announced preclinical and translational data for NDL2, a protein degrader designed to target nuclear PD-L1, according to a company statement. The Sydney-based oncology company said the compound addresses what it describes as a previously unrecognized driver of immunotherapy resistance and metastatic progression.</p><p>The data were generated by Professor Sudha Rao and her team at QIMR Berghofer. In murine triple-negative breast cancer models, NDL2 reduced primary tumor volume by 49% as monotherapy and 73% when combined with anti-PD-1 therapy, with a 50% reduction in lung metastases in the combination setting, according to the company.</p><p>Unlike existing PD-1/PD-L1 antibodies that http://www.streetinsider.com/FDA/Kazia+Therapeutics+reports+preclinical+data+for+cancer+drug+NDL2/25919928.html Fri, 30 Jan 2026 08:00:31 -0500 KZIA http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Announces+Compelling+Preclinical+and+Translational+Data+for+Nuclear+PD-L1+Degrader+%28NDL2%29/25919898.html <div class="xn-content"> <p class="prntac"><i> Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and metastatic progression </i></p><p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Jan. 30, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:KZIA" idsrc="xmltag.org" >Kazia Therapeutics</span> (NASDAQ: KZIA), an oncology-focused pharmaceutical company developing novel therapies for difficult-to-treat cancers, today announced compelling preclinical and translational data supporting the development of NDL2, a potentially first-in-class protein degrader that is designed to selectively eliminate nuclear PD-L1, a previously unrecognized intracellular driver of immunotherapy resistance and metastatic progression that is not addressed by currently approved PD-1/PD-L1 antibodies. Across multiple preclinical models and patient-derived samples, NDL2 demonstrated http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Announces+Compelling+Preclinical+and+Translational+Data+for+Nuclear+PD-L1+Degrader+%28NDL2%29/25919898.html Fri, 30 Jan 2026 08:00:00 -0500 A.06822034 A.40151759 KZIA O.00050368 O.00673961 O.20026344 http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Announces+Compelling+Preclinical+and+Translational+Data+for+Nuclear+PD-L1+Degrader+%28NDL2%29/25919898.html <div class="xn-content"> <p class="prntac"><i> Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and metastatic progression </i></p><p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Jan. 30, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:KZIA" idsrc="xmltag.org" >Kazia Therapeutics</span> (NASDAQ: KZIA), an oncology-focused pharmaceutical company developing novel therapies for difficult-to-treat cancers, today announced compelling preclinical and translational data supporting the development of NDL2, a potentially first-in-class protein degrader that is designed to selectively eliminate nuclear PD-L1, a previously unrecognized intracellular driver of immunotherapy resistance and metastatic progression that is not addressed by currently approved PD-1/PD-L1 antibodies. Across multiple preclinical models and patient-derived samples, NDL2 demonstrated http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Announces+Compelling+Preclinical+and+Translational+Data+for+Nuclear+PD-L1+Degrader+%28NDL2%29/25919898.html Fri, 30 Jan 2026 08:00:00 -0500 A.06822034 A.40151759 KZIA O.00050368 O.00673961 O.20026344 http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Announces+Compelling+Preclinical+and+Translational+Data+for+Nuclear+PD-L1+Degrader+%28NDL2%29/25919898.html <div class="xn-content"> <p class="prntac"><i> Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and metastatic progression </i></p><p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Jan. 30, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:KZIA" idsrc="xmltag.org" >Kazia Therapeutics</span> (NASDAQ: KZIA), an oncology-focused pharmaceutical company developing novel therapies for difficult-to-treat cancers, today announced compelling preclinical and translational data supporting the development of NDL2, a potentially first-in-class protein degrader that is designed to selectively eliminate nuclear PD-L1, a previously unrecognized intracellular driver of immunotherapy resistance and metastatic progression that is not addressed by currently approved PD-1/PD-L1 antibodies. Across multiple preclinical models and patient-derived samples, NDL2 demonstrated http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Announces+Compelling+Preclinical+and+Translational+Data+for+Nuclear+PD-L1+Degrader+%28NDL2%29/25919898.html Fri, 30 Jan 2026 08:00:00 -0500 A.06822034 A.40151759 KZIA O.00050368 O.00673961 O.20026344 http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Announces+Compelling+Preclinical+and+Translational+Data+for+Nuclear+PD-L1+Degrader+%28NDL2%29/25919898.html <div class="xn-content"> <p class="prntac"><i> Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and metastatic progression </i></p><p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Jan. 30, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:KZIA" idsrc="xmltag.org" >Kazia Therapeutics</span> (NASDAQ: KZIA), an oncology-focused pharmaceutical company developing novel therapies for difficult-to-treat cancers, today announced compelling preclinical and translational data supporting the development of NDL2, a potentially first-in-class protein degrader that is designed to selectively eliminate nuclear PD-L1, a previously unrecognized intracellular driver of immunotherapy resistance and metastatic progression that is not addressed by currently approved PD-1/PD-L1 antibodies. Across multiple preclinical models and patient-derived samples, NDL2 demonstrated http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Announces+Compelling+Preclinical+and+Translational+Data+for+Nuclear+PD-L1+Degrader+%28NDL2%29/25919898.html Fri, 30 Jan 2026 08:00:00 -0500 A.06822034 A.40151759 KZIA O.00050368 O.00673961 O.20026344 http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Announces+Compelling+Preclinical+and+Translational+Data+for+Nuclear+PD-L1+Degrader+%28NDL2%29/25919898.html <div class="xn-content"> <p class="prntac"><i> Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and metastatic progression </i></p><p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Jan. 30, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:KZIA" idsrc="xmltag.org" >Kazia Therapeutics</span> (NASDAQ: KZIA), an oncology-focused pharmaceutical company developing novel therapies for difficult-to-treat cancers, today announced compelling preclinical and translational data supporting the development of NDL2, a potentially first-in-class protein degrader that is designed to selectively eliminate nuclear PD-L1, a previously unrecognized intracellular driver of immunotherapy resistance and metastatic progression that is not addressed by currently approved PD-1/PD-L1 antibodies. Across multiple preclinical models and patient-derived samples, NDL2 demonstrated http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Announces+Compelling+Preclinical+and+Translational+Data+for+Nuclear+PD-L1+Degrader+%28NDL2%29/25919898.html Fri, 30 Jan 2026 08:00:00 -0500 A.06822034 A.40151759 KZIA O.00050368 O.00673961 O.20026344 http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Announces+Compelling+Preclinical+and+Translational+Data+for+Nuclear+PD-L1+Degrader+%28NDL2%29/25919898.html <div class="xn-content"> <p class="prntac"><i> Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and metastatic progression </i></p><p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Jan. 30, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:KZIA" idsrc="xmltag.org" >Kazia Therapeutics</span> (NASDAQ: KZIA), an oncology-focused pharmaceutical company developing novel therapies for difficult-to-treat cancers, today announced compelling preclinical and translational data supporting the development of NDL2, a potentially first-in-class protein degrader that is designed to selectively eliminate nuclear PD-L1, a previously unrecognized intracellular driver of immunotherapy resistance and metastatic progression that is not addressed by currently approved PD-1/PD-L1 antibodies. Across multiple preclinical models and patient-derived samples, NDL2 demonstrated http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Announces+Compelling+Preclinical+and+Translational+Data+for+Nuclear+PD-L1+Degrader+%28NDL2%29/25919898.html Fri, 30 Jan 2026 08:00:00 -0500 A.06822034 A.40151759 KZIA O.00050368 O.00673961 O.20026344 http://www.streetinsider.com/PRNewswire/Kazia+Therapeutics+Announces+Compelling+Preclinical+and+Translational+Data+for+Nuclear+PD-L1+Degrader+%28NDL2%29/25919898.html <div class="xn-content"> <p class="prntac"><i> Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and metastatic progression </i></p><p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Jan. 30, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:KZIA" idsrc="xmltag.org" >Kazia Therapeutics</span> (NASDAQ: KZIA), an oncology-focused pharmaceutical company developing novel therapies for difficult-to-treat cancers, today announced compelling preclinical and translational data supporting the development of NDL2, a potentially first-in-class protein degrader that is designed to selectively eliminate nuclear PD-L1, a previously unrecognized intracellular driver of immunotherapy resistance and metastatic progression that is not addressed by currently approved PD-1/PD-L1 antibodies. Across multiple preclinical models and patient-derived samples, NDL2 demonstrated http://www.streetinsider.com/PRNewswire/Kazia+Therapeutics+Announces+Compelling+Preclinical+and+Translational+Data+for+Nuclear+PD-L1+Degrader+%28NDL2%29/25919898.html Fri, 30 Jan 2026 08:00:00 -0500 A.06822034 A.40151759 KZIA O.00050368 O.00673961 O.20026344 http://www.streetinsider.com/PRNewswire/Kazia+Therapeutics+Announces+Compelling+Preclinical+and+Translational+Data+for+Nuclear+PD-L1+Degrader+%28NDL2%29/25919898.html <div class="xn-content"> <p class="prntac"><i> Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and metastatic progression </i></p><p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Jan. 30, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:KZIA" idsrc="xmltag.org" >Kazia Therapeutics</span> (NASDAQ: KZIA), an oncology-focused pharmaceutical company developing novel therapies for difficult-to-treat cancers, today announced compelling preclinical and translational data supporting the development of NDL2, a potentially first-in-class protein degrader that is designed to selectively eliminate nuclear PD-L1, a previously unrecognized intracellular driver of immunotherapy resistance and metastatic progression that is not addressed by currently approved PD-1/PD-L1 antibodies. Across multiple preclinical models and patient-derived samples, NDL2 demonstrated http://www.streetinsider.com/PRNewswire/Kazia+Therapeutics+Announces+Compelling+Preclinical+and+Translational+Data+for+Nuclear+PD-L1+Degrader+%28NDL2%29/25919898.html Fri, 30 Jan 2026 08:00:00 -0500 A.06822034 A.40151759 KZIA O.00050368 O.00673961 O.20026344 http://www.streetinsider.com/PRNewswire/Kazia+Therapeutics+Announces+Compelling+Preclinical+and+Translational+Data+for+Nuclear+PD-L1+Degrader+%28NDL2%29/25919898.html <div class="xn-content"> <p class="prntac"><i> Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and metastatic progression </i></p><p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Jan. 30, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:KZIA" idsrc="xmltag.org" >Kazia Therapeutics</span> (NASDAQ: KZIA), an oncology-focused pharmaceutical company developing novel therapies for difficult-to-treat cancers, today announced compelling preclinical and translational data supporting the development of NDL2, a potentially first-in-class protein degrader that is designed to selectively eliminate nuclear PD-L1, a previously unrecognized intracellular driver of immunotherapy resistance and metastatic progression that is not addressed by currently approved PD-1/PD-L1 antibodies. Across multiple preclinical models and patient-derived samples, NDL2 demonstrated http://www.streetinsider.com/PRNewswire/Kazia+Therapeutics+Announces+Compelling+Preclinical+and+Translational+Data+for+Nuclear+PD-L1+Degrader+%28NDL2%29/25919898.html Fri, 30 Jan 2026 08:00:00 -0500 A.06822034 A.40151759 KZIA O.00050368 O.00673961 O.20026344 http://www.streetinsider.com/PRNewswire/Kazia+Therapeutics+Announces+Compelling+Preclinical+and+Translational+Data+for+Nuclear+PD-L1+Degrader+%28NDL2%29/25919898.html <div class="xn-content"> <p class="prntac"><i> Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and metastatic progression </i></p><p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Jan. 30, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:KZIA" idsrc="xmltag.org" >Kazia Therapeutics</span> (NASDAQ: KZIA), an oncology-focused pharmaceutical company developing novel therapies for difficult-to-treat cancers, today announced compelling preclinical and translational data supporting the development of NDL2, a potentially first-in-class protein degrader that is designed to selectively eliminate nuclear PD-L1, a previously unrecognized intracellular driver of immunotherapy resistance and metastatic progression that is not addressed by currently approved PD-1/PD-L1 antibodies. Across multiple preclinical models and patient-derived samples, NDL2 demonstrated http://www.streetinsider.com/PRNewswire/Kazia+Therapeutics+Announces+Compelling+Preclinical+and+Translational+Data+for+Nuclear+PD-L1+Degrader+%28NDL2%29/25919898.html Fri, 30 Jan 2026 08:00:00 -0500 A.06822034 A.40151759 KZIA O.00050368 O.00673961 O.20026344 http://www.streetinsider.com/PRNewswire/Kazia+Therapeutics+Announces+Compelling+Preclinical+and+Translational+Data+for+Nuclear+PD-L1+Degrader+%28NDL2%29/25919898.html <div class="xn-content"> <p class="prntac"><i> Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and metastatic progression </i></p><p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Jan. 30, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:KZIA" idsrc="xmltag.org" >Kazia Therapeutics</span> (NASDAQ: KZIA), an oncology-focused pharmaceutical company developing novel therapies for difficult-to-treat cancers, today announced compelling preclinical and translational data supporting the development of NDL2, a potentially first-in-class protein degrader that is designed to selectively eliminate nuclear PD-L1, a previously unrecognized intracellular driver of immunotherapy resistance and metastatic progression that is not addressed by currently approved PD-1/PD-L1 antibodies. Across multiple preclinical models and patient-derived samples, NDL2 demonstrated http://www.streetinsider.com/PRNewswire/Kazia+Therapeutics+Announces+Compelling+Preclinical+and+Translational+Data+for+Nuclear+PD-L1+Degrader+%28NDL2%29/25919898.html Fri, 30 Jan 2026 08:00:00 -0500 A.06822034 A.40151759 KZIA O.00050368 O.00673961 O.20026344 http://www.streetinsider.com/PRNewswire/Kazia+Therapeutics+Announces+Compelling+Preclinical+and+Translational+Data+for+Nuclear+PD-L1+Degrader+%28NDL2%29/25919898.html <div class="xn-content"> <p class="prntac"><i> Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and metastatic progression </i></p><p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Jan. 30, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:KZIA" idsrc="xmltag.org" >Kazia Therapeutics</span> (NASDAQ: KZIA), an oncology-focused pharmaceutical company developing novel therapies for difficult-to-treat cancers, today announced compelling preclinical and translational data supporting the development of NDL2, a potentially first-in-class protein degrader that is designed to selectively eliminate nuclear PD-L1, a previously unrecognized intracellular driver of immunotherapy resistance and metastatic progression that is not addressed by currently approved PD-1/PD-L1 antibodies. Across multiple preclinical models and patient-derived samples, NDL2 demonstrated http://www.streetinsider.com/PRNewswire/Kazia+Therapeutics+Announces+Compelling+Preclinical+and+Translational+Data+for+Nuclear+PD-L1+Degrader+%28NDL2%29/25919898.html Fri, 30 Jan 2026 08:00:00 -0500 A.06822034 A.40151759 KZIA O.00050368 O.00673961 O.20026344 http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Kazia+Therapeutics+%28KZIA%29/25903675.html <p>H.C. Wainwright analyst Sean Lee reiterated a Buy rating and $18.00 price target on Kazia Therapeutics (NASDAQ: KZIA).</p><p>The analyst commented: "On January 27, Kazia presented updated results from its Phase 1B study of paxalisib in combination with pembrolizumab and chemotherapy for the treatment of late-stage, metastatic triple-negative breast cancer (TNBC). Recall, the company previously presented initial results in December 2025 where the first treated patient achieved tumor shrinkage of 76%. In the latest update, both evaluable patients treated with 30 mg dose have achieved partial responses following at least 3 cycles of treatment. Furthermore, another patient enrolled under the expanded http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Kazia+Therapeutics+%28KZIA%29/25903675.html Wed, 28 Jan 2026 06:48:32 -0500 KZIA http://www.streetinsider.com/SEC+Filings/Form++424B3++++++KAZIA+THERAPEUTICS+LTD+++++++++++++++/25896703.html si-local-file:///var/storage/secattach/20260127/25896703.html http://www.streetinsider.com/SEC+Filings/Form++424B3++++++KAZIA+THERAPEUTICS+LTD+++++++++++++++/25896703.html Tue, 27 Jan 2026 08:26:00 -0500 KZIA O.00673961 http://www.streetinsider.com/SEC+Filings/Form++424B3++++++KAZIA+THERAPEUTICS+LTD+++++++++++++++/25896703.html si-local-file:///var/storage/secattach/20260127/25896703.html http://www.streetinsider.com/SEC+Filings/Form++424B3++++++KAZIA+THERAPEUTICS+LTD+++++++++++++++/25896703.html Tue, 27 Jan 2026 08:26:00 -0500 KZIA O.00673961 http://www.streetinsider.com/SEC+Filings/Form++424B3++++++KAZIA+THERAPEUTICS+LTD+++++++++++++++/25896695.html si-local-file:///var/storage/secattach/20260127/25896695.html http://www.streetinsider.com/SEC+Filings/Form++424B3++++++KAZIA+THERAPEUTICS+LTD+++++++++++++++/25896695.html Tue, 27 Jan 2026 08:24:00 -0500 KZIA O.00673961 http://www.streetinsider.com/SEC+Filings/Form++424B3++++++KAZIA+THERAPEUTICS+LTD+++++++++++++++/25896695.html si-local-file:///var/storage/secattach/20260127/25896695.html http://www.streetinsider.com/SEC+Filings/Form++424B3++++++KAZIA+THERAPEUTICS+LTD+++++++++++++++/25896695.html Tue, 27 Jan 2026 08:24:00 -0500 KZIA O.00673961